Supplemental Material is available online (<https://doi.org/10.1289/EHP2619>).

These authors contributed equally to this work.

The authors declare they have no actual or potential competing financial interests.

**Note to readers with disabilities:** *EHP* strives to ensure that all journal content is accessible to all readers. However, some figures and Supplemental Material published in *EHP* articles may not conform to [508 standards](http://ehp.niehs.nih.gov/accessibility/) due to the complexity of the information being presented. If you need assistance accessing journal content, please contact <ehponline@niehs.nih.gov>. Our staﬀ will work with you to assess and meet your accessibility needs within 3 working days.

Introduction {#s1}
============

Accumulating evidence documents the important role of endocrine-disrupting chemicals (EDCs) in the pathogenesis of obesity, type 2 diabetes (T2D), and other metabolic conditions ([@c5]; [@c20]). The EDCs exert their detrimental effects primarily through modulating nuclear receptors, such as estrogen receptors and peroxisome proliferator-activated receptor $\gamma$ ($\text{PPAR}\gamma$) ([@c5]; [@c20]). Although the relationship of EDCs, such as polychlorinated biphenyls, with T2D or obesity have been extensively examined in basic science research and prospective human studies ([@c5]; [@c20]; [@c33]; [@c76]), evidence for perfluoroalkyl substances (PFASs) is limited. Blood concentrations of these ubiquitous environmental pollutants are declining in Americans overall, but they remain detectable in almost the entire population ([@c3]; [@c27]; [@c34]; [@c46]). These chemicals possess endocrine-disrupting properties and are known to activate PPARs in rodents ([@c22]; [@c28]; [@c31]; [@c53]). The mechanistic pathways may also involve activation and disruption of the functions of other regulators ([@c50]; [@c58]; [@c62]; [@c70]; [@c77]) of lipid and glucose metabolism ([@c19]; [@c24]; [@c52]). Despite the evidence indicating potentially obesogenic and diabetogenic effects of PFASs, most data linking PFAS exposure with T2D are derived from cross-sectional studies, with equivocal findings ([@c4]; [@c7]; [@c8]; [@c26]; [@c36]; [@c63]; [@c79]).

To address prospective associations between PFASs and T2D risk, we conducted a prospective nested case--control study of U.S. female nurses participating in the Nurses' Health Study II (NHSII) and examined the hypothesis that higher plasma concentrations of PFASs are associated with a higher T2D risk. We also evaluated potential demographic and lifestyle determinants of PFAS exposures that have been reported in other cohorts of women ([@c32]; [@c38]), including age, region of residence, breastfeeding duration, body weight, and diet.

Methods {#s2}
=======

Study Population {#s2.1}
----------------

The NHSII is an ongoing prospective cohort study that consists of 116,430 U.S. female nurses enrolled in 1989 when they responded to a questionnaire inquiring about a multitude of variables, including body weight and height, demographics, lifestyle habits, history of chronic diseases and medication use (Zong et al., unpublished data, 2018). Follow-up questionnaires were administered biennially to update the lifestyle and medical history information. A total of 29,611 NHSII participants 32--52 y of age provided blood samples in 1995--2000, which were transmitted to a central biorepository via overnight courier. Upon arrival, the samples were immediately processed and aliquoted into cryotubes, which were stored in the vapor phase of liquid nitrogen freezers at $\leq - 130{^\circ}C$ ($\leq - 207.4{^\circ}F$). Among participants who provided blood samples, a high follow-up rate of $> 90\%$ has been maintained.

Nested Case--Control Study Design {#s2.2}
---------------------------------

Pariticipants who provided blood samples and were free of self-reported prevalent diabetes, cardiovascular disease, and cancer at sample collection were eligible for the current investigation. Among these participants, we prospectively identified and confirmed 793 T2D cases (as explained in detail below) during biennial follow-up from blood collection to June 2011 (range: 1--16 y, $\text{mean} \pm \text{SD}$: $6.7 \pm 3.7\; y$). One control was randomly selected for each case using the risk-set sampling approach ([@c49]). Cases and controls were individually matched for age at blood sample collection, month of sample collection (March--May, June--August, September--November, and December--February), fasting status (yes/no), ethnicity, menopausal status and hormone replacement therapy (HRT; premenopause, postmenopause and never used HRT, postmenopause and former or current HRT use, or missing). Menopausal status and HRT in cases were matched to controls, as these factors may affect associations for various biomarkers to be examined in the same nested case--control study ([@c55]). To minimize reverse causation bias, T2D cases diagnosed within the first year following the blood sample collection were excluded.

The study protocol was approved by the institutional review board of the Brigham and Women's Hospital and the Human Subjects Committee Review Board of Harvard T.H. Chan School of Public Health.

Ascertainment of T2D {#s2.3}
--------------------

If participants reported having a T2D diagnosis in follow-up questionnaires, they were then sent a validated supplemental questionnaire ([@c37]) to confirm or refute the self-report. We used at least one of the following American Diabetes Association (ADA) 1998 criteria to confirm T2D diagnosis based on self-reported information from a supplemental questionnaire: *a*) an elevated glucose concentration (fasting plasma glucose $\geq 7.0\,\text{mmol}/L$, random plasma glucose $\geq 11.1\,\text{mmol}/L$, or plasma glucose $\geq 11.1\,\text{mmol}/L$ after an oral glucose load) and at least one symptom related to diabetes; *b*) no symptoms, but elevated plasma glucose concentrations on two separate occasions; or *c*) treatment with insulin or oral hypoglycemic medication. In our nested case--control study, only confirmed T2D cases were included, in which 30 (3.8%), 647 (81.6%), and 655 (82.6%) met criterion a, b, and c, respectively. In the validation study of T2D diagnosis, 61 of 62 (98.3%) questionnaire-confirmed cases of T2D were reconfirmed after an endocrinologist reviewed the medical records without the information from the supplementary questionnaire ([@c37]).

Assessment of Diet {#s2.4}
------------------

A validated semiquantitative food frequency questionnaire (sFFQ) ([@c74]) was first administered in 1991 and sent to participants quadrennially thereafter to update dietary habits. In the sFFQs, we asked about average consumption frequency of about 130 food items during the past year, with a prespecified serving size for each item. Good validity and reproducibility of the assessments of individual food items, including fruits, vegetables, red meats, seafood, beverages, and popcorn and other grain products, have been demonstrated in validation studies ([@c14]; [@c16]; [@c56]). Nutrient intake was estimated by multiplying the consumption frequency of each relevant food item by its contents of the nutrient and then summing intake of the nutrient across all food items ([@c73]). We derived an alternative healthy eating index (AHEI) score to evaluate the overall quality of diet ([@c6]). This score summarizes the consumption of 11 foods and nutrients most predictive of chronic disease risk, including vegetables, fruits, whole grains, sugar-sweetened beverages and fruit juice, nuts and legumes, red and processed meat, *trans* fats, long-chain n-3 fats, polyunsaturated fats, sodium, and alcohol. A higher score indicates a better diet quality.

Laboratory Measurements {#s2.5}
-----------------------

In the current study, plasma concentrations of PFASs were measured using on-line solid phase extraction and liquid chromatography coupled to a triple quadropole mass spectrometer ([@c18]; [@c71]), with minor modifications. We quantified five PFASs that have a high detection rate ($> 99\%$) and can be reliably measured in the general population: perfluorooctane sulfate (PFOS), perfluorooctanoic acid (PFOA), perfluorohexanesulfonate (PFHxS), perfluorononanoic acid (PFNA), and perfluorodecanoic acid (PFDA). Concentrations of minor PFASs with a lower detection rate and/or higher laboratory measurement errors \[coefficients of variation (CVs) $\geq 20\%$\] are provided in Table S1. Several plasma T2D risk markers were also measured at baseline: hemoglobin A1c (HbA1c), total cholesterol, and triacylglycerol were measured on the Roche P Modular system (Roche Diagnostics), total adiponectin concentrations were measured using an enzyme-linked immunosorbent assay (ALPCO), and fasting insulin was measured by a radioimmunoassay (Linco). The intraassay CVs ranged from 0.7% for insulin to 4.0% for total adiponectin.

To ensure that the laboratory assessments of biomarkers are free of systematic measurement error, we processed and analyzed samples of matched case--control pairs in the same analytical run. Within each batch, matched samples were assayed by the same technician in a random sequence under identical conditions. We placed splits of blinded quality control samples in the batches of the case--control samples to monitor the quality of these assays. The average intraassay CV% were 6.1% for PFOS, 8.7% for PFOA, 9.7% for PFHxS, 12.5% for PFNA, and 14.4% for PFDA. Internal quality assurance data using the NIST SRM1958 showed average interassay CV% of 7.4% for PFOS, 7.2% for PFOA, 4.0% for PFHxS and 6.5% for PFNA. Although no certified value is given for PFDA, this peak shows a CV% of 10.6%.

Within-Person Reproducibility of PFASs {#s2.6}
--------------------------------------

In a pilot study, we measured PFAS concentrations in a random sample of 58 participants who provided two blood specimens collected 1--2 y apart. The study design has been described elsewhere ([@c82]). Samples from the same individuals were handled identically, shipped and processed in the same batch, and placed on the same plate with random position. The lab personnel were blinded to sample status. Intraclass correlation coefficients (ICCs) between two samples were calculated and used to evaluate the reproducibility of the PFAS analyses.

Statistical Methods {#s2.7}
-------------------

We replaced PFAS values below the detection limit ($0.015\,\text{ng}/{mL}$) by the detection limit divided by the square root of 2. Given the imprecision of the PFAS measurements, we adjusted the PFAS concentrations for batch effects ([@c54]). According to this method, we first ran a linear regression model to regress PFAS concentrations on batch indicator dummy variables. PFAS concentrations were then recalibrated by subtracting the difference between the coefficient of each individual batch and the average of the coefficients of all batches. All analyses were based on recalibrated values of PFASs unless otherwise indicated.

In controls, we calculated Spearman correlation coefficients ($r_{s}$) to evaluate intercorrelations among PFASs. To examine whether PFAS exposure is associated with insulin resistance, glucose homeostasis, and dyslipidemia that predispose T2D development, we calculated $r_{s}$ of PFASs with total adiponectin, fasting insulin, HbA1c, and blood lipids. We explored the association of plasma PFAS concentrations with major demographic and lifestyle determinants that have been reported in other cohorts of women ([@c32]; [@c38]), including age, states of residence, breastfeeding history, baseline body mass index (BMI), and overall diet quality measured by AHEI, by calculating least-square means of PFAS concentrations by categories of the determinants using a generalized linear regression model. Covariates were primarily derived from the questionnaire administered in 1995 (or questionnaires administered closest to 1995). States of residence were classified as coastal (AL, AK, CA, CT, DE, FL, GA, HI, ME, MD, MA, NH, NJ, NC, OR, RI, SC, VA, and WA), Great Lakes region (IL, IN, MI, MN, NY, OH, PA, and WI), and inland (all other states). Lifetime breastfeeding duration in months was obtained from the 1993 questionnaire using the question "How many months in total (all births combined) did you breast feed?". To account for additional breastfeeding between 1993 and the blood draw, we further adjusted for number of births during this period using subsequent questionnaires. The multivariate models simultaneously adjusted for age, BMI, breastfeeding history, number of births, states of residence, and AHEI, in addition to matching factors. Matching factors were included to account for potential variations from the matching design. Because of the right-skewed distributions, PFAS values were log transformed (base 10) before the analysis, and transformed back to the original scale for presentation. We also examined individual food items, primarily seafood and popcorn as known dietary sources of PFAS exposure ([@c23]; [@c47]; [@c61]; [@c67]; [@c68]). Finally, we calculated $r_{s}$ between plasma PFASs and intakes of all foods collected in the sFFQ for an overview of PFAS--diet associations. Primary food groups included dairy foods, fruits, vegetables, eggs and meats, breads and cereals, beverages, and sweets and baked goods. These analyses were limited to controls to minimize the possibility that preclinical T2D stages of cases affect plasma PFAS concentrations and T2D risk markers. In addition, controls are more representative of the overall source population.

The associations between plasma PFAS concentrations and T2D risk were evaluated using conditional logistic regression. The models were adjusted for the matching factors, and we further controlled for predictors of PFAS concentrations and/or known risk factors of T2D, including family history of diabetes (yes, or no), oral contraceptive use (never used, past user, or current user), breastfeeding duration at blood draw (nulliparous or parous without breastfeeding, $\leq 11\,\text{months}$, or $\geq 12\,\text{months}$) and number of children delivered after 1993 (0, 1, or $\geq 2$), state of residence (coastal, Great Lakes region, or inland), smoking status (never, former, or current), alcohol intake (abstainer, $< 5.0\; g/\text{day}$, $5.0–14.9\; g/\text{day}$, or $\geq 15.0\; g/\text{day}$), metabolic equivalent of task for physical activity (MET-h/wk; $< 3$, 3--8.9, 9--17.9, 18--26.9, or $\geq 27$), baseline BMI (${{kg}/m}^{2}$; $< 23.0$, 23.0--24.9, 25.0--29.9, 30.0--34.9, or $\geq 35.0$), and AHEI score (in quintiles). Participants were categorized into tertiles according to the distribution of PFAS concentrations among controls. *p*-Values for linear trend were calculated by modeling the median value of each tertile as a continuous variable. In addition, we modeled log-transformed PFAS concentrations as continuous variables. Dose--response relationship of PFASs with T2D risk was evaluated using restricted cubic spline regressions with 3 knots after excluding participants in the lowest 2.5% and highest 2.5% of PFAS concentrations to minimize potential impact of outliers ([@c12]), and *p* for nonlinearity was examined with a likelihood ratio test (LRT) comparing the model with linear term only to the model with the linear plus cubic spline terms.

Relevant secondary analyses were performed. We stratified the PFAS--T2D analyses by median time of follow-up (which was 2005) and by the median AHEI (which was 48). Statistical significance of effect modification (*p* for interaction) was evaluated by LRT, comparing models with and without interaction terms between tertiles of PFAS concentrations and the effect modifiers. Lastly, in a sensitivity analysis, we excluded batches with higher laboratory imprecision (within-batch CV $\geq 20\%$) and repeated the analysis using measured PFAS concentrations that were not adjusted for batch effects.

All *p*-values were two-sided. Data were analyzed with the Statistical Analysis Systems software package (version 9.4; SAS Institute, Inc.).

Results {#s3}
=======

The repeated PFAS measurements in two blood samples collected 1--2 y apart demonstrated high reproducibility: The ICCs were 0.91 for PFOS, 0.90 for PFOA, 0.94 for PFHxS, 0.87 for PFNA, and 0.82 for PFDA. [Table 1](#t1){ref-type="table"} shows the characteristics of T2D cases and controls at the study baseline. Apart from matching factors, T2D cases were less likely to live in coastal states and had a high-risk profile, such as a higher BMI; lower physical activity; shorter breastfeeding duration; a poorer AHEI score; higher plasma concentrations of total cholesterol, triglycerides, HbA1c, and fasting insulin; and lower total adiponectin than controls. PFASs were detectable among all participants, with the exception of PFDA, which was not detected in seven cases and five controls. PFOS was the predominant PFAS with the highest average concentrations, whereas PFDA concentrations were the lowest in this population.

###### 

Characteristics of type 2 diabetes cases and controls at blood sample collection in the Nurses' Health Study II.

Table 1 lists characteristics in the first column; the corresponding values for cases (n equals 793), controls (n equals 793), and p values are listed in the other columns.

  Characteristics                                                       Cases ($n = 793$)    Controls ($n = 793$)   *p*-Value[^*a*^](#t1n1){ref-type="table-fn"}
  ------------------------------------------------------------------- --------------------- ---------------------- ----------------------------------------------
  Age at blood sample collection (y)                                     $45.3 \pm 4.4$         $45.3 \pm 4.4$                          0.97
  Caucasians (%)                                                                                                                        0.20
   Yes                                                                     756 (95.3)             766 (96.6)                              
   No                                                                       37 (4.7)               27 (3.4)                               
  Fasting $\geq 8\; h$ at blood draw (%)                                                                                                0.21
   Yes                                                                     522 (69.0)             559 (71.9)                              
   No                                                                      271 (31.0)             234 (28.1)                              
  Menopausal status and hormone use (%)                                                                                                   
   Premenopause                                                            538 (67.8)             538 (67.8)                          $> 0.99$
   Postmenopausal, never used                                               29 (3.7)               29 (3.7)                               
   Postmenopausal, current or past user                                    122 (15.4)             122 (15.4)                              
   Missing                                                                 104 (13.1)             104 (13.1)                              
  States of residence[^*b*^](#t1n2){ref-type="table-fn"}                                                                                0.03
   Coastal                                                                 124 (15.6)             164 (20.7)                              
   Great Lakes region                                                      442 (55.7)             411 (51.8)                              
   Inland                                                                  227 (28.6)             218 (27.5)                              
  BMI (${{kg}/m}^{2}$)                                                   $32.6 \pm 6.8$         $25.5 \pm 5.4$                       $< 0.001$
  Family history of diabetes (%)                                                                                                     $< 0.001$
   Yes                                                                     257 (32.4)             132 (16.7)                              
   No                                                                      536 (67.6)             661 (83.3)                              
  Physical activity (MET-h/wk)                                           $16.1 \pm 25.8$       $20.7 \pm 28.2$                         0.001
  Smoking status (%)                                                                                                                      
   Never smoked                                                            499 (62.9)             515 (64.9)                            0.02
   Former smoker                                                           195 (24.6)             212 (26.7)                              
   Current smoker                                                           99 (12.5)              66 (8.3)                               
  Alcohol intake (%)                                                                                                                 $< 0.001$
   Abstainers                                                              350 (44.1)             263 (33.3)                              
   $0.1–4.9\; g/d$                                                         348 (43.9)             376 (47.4)                              
   $5.0–9.9\; g/d$                                                          51 (6.4)              87 (11.0)                               
   $\geq 10\; g/d$                                                          44 (5.6)               67 (8.4)                               
  Breastfeeding duration through blood draw (%)                                                                                         0.06
   Nulliparous or parous without breastfeeding                             287 (36.2)             254 (32.0)                              
   $\leq 11\,\text{months}$                                                256 (32.3)             245 (30.9)                              
   $\geq 12\,\text{months}$                                                211 (26.6)             259 (32.7)                              
   Missing                                                                  39 (4.9)               35 (4.4)                               
  Number of births after 1993                                            $0.08 \pm 0.35$       $0.06 \pm 0.29$                          0.38
  Use of oral contraceptive (%)                                                                                                         0.03
   Current user                                                            106 (13.4)             94 (11.9)                               
   Former user                                                             668 (84.2)             661 (83.4)                              
   Never used                                                               19 (2.4)               38 (4.8)                               
  AHEI score                                                             $46.7 \pm 9.6$         $49.4 \pm 9.9$                       $< 0.001$
  Total cholesterol (g/L)                                               2.14 (1.89--2.38)     2.03 (1.80--2.28)                      $< 0.001$
  Triglycerides (g/L)                                                   1.79 (1.26--2.59)     1.06 (0.75--1.55)                      $< 0.001$
  Total adiponectin (ng/mL)[^*c*^](#t1n3){ref-type="table-fn"}          4.19 (3.22--5.90)     7.23 (5.22--9.93)                      $< 0.001$
  HbA1c (%)[^c^](#t1n3){ref-type="table-fn"}                            5.81 (5.58--6.13)     5.41 (5.25--5.57)                      $< 0.001$
  Fasting insulin ($\mu U/{mL}$)[^*c*^](#t1n3){ref-type="table-fn"}    13.49 (8.06--19.46)    6.00 (4.03--8.89)                      $< 0.001$
  PFASs (ng/mL)                                                                                                                           
   PFOS                                                                 35.7 (26.4--48.3)     33.1 (23.3--46.8)                        0.003
   PFOA                                                                 4.96 (3.70--6.67)     4.57 (3.35--6.16)                      $< 0.001$
   PFHxS                                                                2.15 (1.35--3.79)     2.01 (1.32--3.51)                         0.16
   PFNA[^*a*^](#t1n1){ref-type="table-fn"}                              0.60 (0.44--0.85)     0.61 (0.42--0.88)                         0.89
   PFDA                                                                 0.13 (0.09--0.19)     0.16 (0.11--0.23)                      $< 0.001$

Note: Continuous variables are shown as $\text{mean} \pm \text{SD}$ or median interquartile ranges (IQR), and categorical variables are shown as number (%). AHEI, alternative healthy eating index; BMI, body mass index; HbA1c, hemoglobin A1c; IQR, interquartile range; MET, metabolic equivalent task; PFAS, perfluoroalkyl substances; PFDA, perfluorodecanoic acid; PFHxS, perfluorohexane sulfonic acid; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate; SD, standard deviation.

*p*-Value estimates are based on Student's *t*-test for variables expressed as $\text{mean} \pm \text{SD}$, Wilcoxon rank--sum test for variables expressed as median (IQR), or Pearson $\chi 2$ test for variables expressed as percentages. Data are complete unless otherwise indicated.

Coastal states: AL, AK, CA, CT, DE, FL, GA, HI, ME, MD, MA, NH, NJ, NC, OR, RI, SC, VA, and WA; Great Lakes region states: IL, IN, MI, MN, NY, OH, PA, and WI; and inland states: all other states.

Missing data for cases: $n = 28$ for HbA1c, $n = 250$ for fasting insulin, and $n = 7$ for PFNA; for controls: $n = 1$ for total adiponectin, $n = 42$ for HbA1c, $n = 247$ for fasting insulin, and $n = 5$ for PFNA.

In [Table 2](#t2){ref-type="table"}, we show the PFAS concentrations by age, states of residence, BMI, breastfeeding history, AHEI, and consumptions of seafood and popcorn among controls. After multivariate adjustment for covariates, increasing age correlated with higher PFHxS ($p_{\text{trend}} = 0.04$) but not with other PFASs. Participants living in inland states had higher PFHxS, PFNA, and PFDA concentrations than those living in coastal regions. None of the PFASs was associated with baseline BMI, except for PFDA that was associated with lower BMI. Longer breastfeeding duration was inversely associated with all PFASs except PFDA. Higher AHEI was associated with lower PFOS concentrations. More frequent seafood consumption was associated with higher PFHxS and PFNA concentrations, and higher popcorn intake was linked to higher PFOS concentrations. Correlation coefficients between other individual food items and PFAS concentrations were not significant after Bonferroni correction of *p*-values (see Table S2).

###### 

Plasma PFAS concentrations \[median (IQR)\] in ng/mL by demographic, lifestyle, and dietary factors among controls.

Table 2 lists variables in the first column; the corresponding n values and PFAS, namely, PFOS, PFOA, PFHxS, PFNA, and PFDA are listed in the other columns.

  Variable                                                                                $n$          PFOS                PFOA                PFHxS               PFNA                PFDA
  --------------------------------------------------------------------------------------- ----- ------------------- ------------------- ------------------- ------------------- -------------------
  Age at baseline (y)                                                                                                                                                                     
   $< 40$                                                                                 105    32.9 (29.3--36.8)   4.37 (3.89--4.92)   2.06 (1.75--2.44)   0.60 (0.53--0.67)   0.16 (0.14--0.18)
   40--50                                                                                 555    34.1 (32.5--35.7)   4.94 (4.71--5.18)   2.22 (2.07--2.37)   0.62 (0.59--0.65)   0.16 (0.15--0.17)
   $> 50$                                                                                 133    30.8 (27.7--34.2)   4.22 (3.78--4.71)   2.64 (2.26--3.09)   0.66 (0.59--0.73)   0.16 (0.14--0.18)
   *p*-Trend[^*a*^](#t2n1){ref-type="table-fn"}                                                        0.39                0.60                0.04                0.28                0.92
  States of residence[^*b*^](#t2n2){ref-type="table-fn"}                                                                                                                                  
   Coastal                                                                                164    34.9 (32.1--38.0)   4.62 (4.23--5.05)   2.09 (1.85--2.37)   0.66 (0.60--0.72)   0.18 (0.16--0.20)
   Lake                                                                                   411    32.8 (31.1--34.6)   4.68 (4.43--4.95)   2.22 (2.05--2.40)   0.64 (0.61--0.68)   0.16 (0.15--0.17)
   *p* vs. Coastal[^*c*^](#t2n3){ref-type="table-fn"}                                                  0.24                0.81                0.45                0.59                0.10
   Inland                                                                                 218    33.1 (30.7--35.7)   4.93 (4.56--5.33)   2.49 (2.23--2.78)   0.56 (0.52--0.61)   0.14 (0.13--0.16)
   *p* vs. Coastal[^*c*^](#t2n3){ref-type="table-fn"}                                                  0.37                0.29                0.04                0.008               0.002
  BMI at baseline \[${{kg}/m}^{2}$\]                                                                                                                                                      
   $< 25$                                                                                 455    32.5 (31.0--34.2)   4.61 (4.37--4.85)   2.18 (2.02--2.35)   0.62 (0.59--0.65)   0.17 (0.16--0.18)
   25--30                                                                                 211    34.5 (32.1--37.1)   5.08 (4.71--5.49)   2.40 (2.15--2.67)   0.64 (0.60--0.70)   0.16 (0.14--0.17)
   $> 30$                                                                                 127    34.2 (31.1--37.6)   4.65 (4.21--5.14)   2.35 (2.04--2.70)   0.60 (0.54--0.66)   0.14 (0.13--0.16)
   *p*-Trend[^*a*^](#t2n1){ref-type="table-fn"}                                                        0.23                 0.4                0.21                0.81                0.008
  Breastfeeding duration through blood draw (months)[^*d*^](#t2n4){ref-type="table-fn"}                                                                                                   
   Nulliparous or parous without breastfeeding                                            254    34.1 (31.8--36.4)   5.05 (4.70--5.42)   2.39 (2.17--2.65)   0.67 (0.62--0.72)   0.16 (0.15--0.18)
   $\leq 11$                                                                              245    35.6 (33.3--38.1)   4.94 (4.60--5.31)   2.36 (2.14--2.61)   0.62 (0.58--0.67)   0.16 (0.15--0.17)
   $\geq 12$                                                                              259    30.7 (28.8--32.8)   4.33 (4.03--4.64)   2.01 (1.82--2.22)   0.56 (0.53--0.61)   0.15 (0.14--0.16)
   *p*-Trend[^*a*^](#t2n1){ref-type="table-fn"}                                                        0.04                0.003               0.02                0.001               0.14
  AHEI                                                                                                                                                                                    
   Tertile 1, 38.8 (34.8--41.0)                                                           229    35.2 (32.8--37.8)   4.82 (4.47--5.19)   2.23 (2.01--2.48)   0.59 (0.55--0.64)   0.15 (0.14--0.16)
   Tertile 2, 48.6 (45.8--49.9)                                                           255    33.8 (31.6--36.1)   4.67 (4.36--5.01)   2.40 (2.18--2.66)   0.62 (0.58--0.67)   0.16 (0.15--0.17)
   Tertile 3, 58.4 (54.6--62.8)                                                           309    31.6 (29.7--33.6)   4.73 (4.44--5.04)   2.17 (1.98--2.38)   0.64 (0.60--0.69)   0.16 (0.15--0.18)
   *p*-Trend[^*a*^](#t2n1){ref-type="table-fn"}                                                        0.02                0.76                0.63                0.08                0.11
  Seafood intake (servings/week)                                                                                                                                                          
   Tertile 1, 0.47 (0.23--0.70)                                                           237    33.9 (31.6--36.4)   4.87 (4.52--5.23)   2.15 (1.94--2.38)   0.57 (0.53--0.61)   0.15 (0.14--0.16)
   Tertile 2, 1.20 (0.97--1.43)                                                           310    32.9 (31.0--35.0)   4.68 (4.39--4.99)   2.10 (1.92--2.30)   0.62 (0.58--0.66)   0.16 (0.15--0.17)
   Tertile 3, 2.47 (1.97--3.23)                                                           246    33.3 (31.1--35.6)   4.68 (4.36--5.03)   2.61 (2.36--2.88)   0.67 (0.63--0.72)   0.17 (0.16--0.18)
   *p*-Trend[^*a*^](#t2n1){ref-type="table-fn"}                                                        0.72                0.47                0.009               0.002               0.03
  Popcorn intake (servings/week)                                                                                                                                                          
   Tertile 1, 0.23 (0.22--0.47)                                                           293    29.7 (27.9--31.6)   4.65 (4.36--4.97)   2.46 (2.24--2.70)   0.65 (0.60--0.69)   0.16 (0.15--0.17)
   Tertile 2, 0.73 (0.73--1.00)                                                           288    32.2 (30.3--34.2)   4.58 (4.29--4.89)   2.13 (1.94--2.34)   0.60 (0.57--0.65)   0.15 (0.14--0.16)
   Tertile 3, 2.98 (2.00--3.50)                                                           212    40.9 (38.1--44.0)   5.09 (4.71--5.49)   2.18 (1.96--2.44)   0.61 (0.56--0.66)   0.16 (0.15--0.18)
   *p*-Trend[^*a*^](#t2n1){ref-type="table-fn"}                                                      $< 0.001$             0.11                0.08                0.24                0.96

Note: Least-squared means of batched-corrected plasma PFASs were estimated using generalized linear regression model with adjustment of age (in years), ethnicity (white, or others), time of blood draw (March--May, June--August, September--November, and December--February), fasting status (yes, or no), states of residence (coastal, Great Lakes region, or inland), family history of diabetes (yes, or no), menopausal status and postmenopausal hormone use (premenopause, postmenopause and never use hormone, postmenopause and former or current use hormone, or missing), oral contraceptive use (never used, past user, or current user), breastfeeding duration (nulliparous or parous without breastfeeding, $\leq 11\,\text{months}$, or $\geq 12\,\text{months}$), number of children delivered after 1993 (0, 1, or $\geq 2$), BMI (${{kg}/m}^{2}$, $< 23.0$, 23.0--24.9, 25.0--29.9, 30.0--34.9, or $\geq 35.0$), and AHEI (alternative health eating index, in quintiles) without self-adjustment. AHEI was not adjusted for when modeling seafood or popcorn intake as predictors. AHEI, alternative healthy eating index; BMI, body mass index; IQR, interquartile range; PFAS, perfluoroalkyl substances; PFDA, perfluorodecanoic acid; PFHxS, perfluorohexane sulfonic acid; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate.

*p*-Values for trend were calculated by modeling the ordinal values of categories as continuous variables.

Coastal states: AL, AK, CA, CT, DE, FL, GA, HI, ME, MD, MA, NH, NJ, NC, OR, RI, SC, VA, and WA; Great Lakes region states: IL, IN, MI, MN, NY, OH, PA, and WI; and inland states: all other states.

*p*-Values for between-group differences comparing the Great Lakes region (first) and inland (second) residents with coastal residents.

Missing data: $n = 39$ missing because of women who did not remember breastfeeding duration or replied "pass through."

Among controls, individual PFASs were significantly intercorrelated with one another ($r_{s}$ ranging from 0.20 to 0.67; see Table S3). In general, PFAS concentrations were not significantly correlated with total adiponectin, fasting insulin, or HbA1c at baseline. We found significant correlations between certain PFASs and blood lipids, although none of these $r_{s}$ values was above 0.15.

In crude analyses where only the matching factors were considered in multivariate adjustment, PFOS and PFOA concentrations were significantly associated with a higher T2D risk ([Table 3](#t3){ref-type="table"}). In contrast, higher concentrations of PFDA were associated with a lower T2D risk in the crude model. After adjustment for other covariates, the associations were slightly attenuated but remained statistically significant for PFOS and PFOA; comparing extreme tertiles, the ORs were 1.62 \[95% confidence interval (CI): 1.09, 2.41\] and 1.54 (95% CI: 1.04, 2.28), respectively. The association for PFDA was attenuated toward the null after the same adjustment.

###### 

Associations between plasma PFAS concentrations and incident type 2 diabetes risk in the Nurses' Health Study II.

Table 3 lists PFAS exposure in the first column; the corresponding range (median) in nanograms per milliliter, number of cases, number of controls, and OR (95 percent confidence intervals) for Model 1 and Model 2 are listed in the other columns.

  Exposure                                                      Range (median) (ng/mL)   Cases ($n$)   Controls ($n$)   Model 1 \[OR (95% CI)\][^*a*^](#t3n1){ref-type="table-fn"}   Model 2 \[OR (95% CI)\][^*a*^](#t3n1){ref-type="table-fn"}
  ------------------------------------------------------------ ------------------------ ------------- ---------------- ------------------------------------------------------------ ------------------------------------------------------------
  PFOS                                                                                                                                                                                                            
   Tertile 1                                                      6.04--26.3 (19.7)          199            264                                 Reference                                                    Reference
   Tertile 2                                                      26.3--41.4 (33.1)          285            265                             1.50 (1.16, 1.94)                                            1.63 (1.25, 2.12)
   Tertile 3                                                       41.4--421 (56.3)          309            264                             1.57 (1.07, 2.30)                                            1.62 (1.09, 2.41)
   *p*-Trend[^*b*^](#t3n2){ref-type="table-fn"}                                                                                                 $< 0.0001$                                                      0.02
   $\text{Log}_{10}$ PFOS[^*c*^](#t3n3){ref-type="table-fn"}                                                                                1.18 (1.06, 1.31)                                            1.15 (0.98, 1.35)
   *p*-Value                                                                                                                                      0.002                                                         0.08
  PFOA                                                                                                                                                                                                            
   Tertile 1                                                      0.99--3.76 (2.89)          215            264                                 Reference                                                    Reference
   Tertile 2                                                      3.76--5.48 (4.57)          262            265                             1.24 (0.96, 1.60)                                            1.27 (0.87, 1.86)
   Tertile 3                                                       5.48--112 (7.36)          316            264                             1.59 (1.23, 2.05)                                            1.54 (1.04, 2.28)
   *p*-Trend[^*b*^](#t3n2){ref-type="table-fn"}                                                                                                   0.0003                                                        0.03
   $\text{Log}_{10}$ PFOS[^*c*^](#t3n3){ref-type="table-fn"}                                                                                1.22 (1.09, 1.35)                                            1.24 (1.06, 1.45)
   *p*-Value                                                                                                                                      0.0004                                                       0.009
  PFHxS                                                                                                                                                                                                           
   Tertile 1                                                      0.32--1.49 (1.09)          240            264                                 Reference                                                    Reference
   Tertile 2                                                      1.49--2.90 (2.01)          277            265                             1.09 (0.85, 1.40)                                            1.15 (0.79, 1.67)
   Tertile 3                                                       2.91--429 (4.77)          276            264                             1.14 (0.88, 1.46)                                            1.26 (0.86, 1.86)
   *p*-Trend[^*b*^](#t3n2){ref-type="table-fn"}                                                                                                    0.33                                                         0.24
   $\text{Log}_{10}$ PFOS[^*c*^](#t3n3){ref-type="table-fn"}                                                                                1.08 (0.97, 1.20)                                            1.05 (0.89, 1.23)
   *p*-Value                                                                                                                                       0.16                                                         0.58
  PFNA                                                                                                                                                                                                            
   Tertile 1                                                      0.09--0.47 (0.37)          240            264                                 Reference                                                    Reference
   Tertile 2                                                      0.47--0.77 (0.61)          301            265                             1.21 (0.94, 1.54)                                            1.08 (0.75, 1.56)
   Tertile 3                                                      0.77--7.74 (1.05)          252            264                             1.00 (0.76, 1.31)                                            0.99 (0.67, 1.48)
   *p*-Trend[^*b*^](#t3n2){ref-type="table-fn"}                                                                                                    0.98                                                         0.97
   $\text{Log}_{10}$ PFOS[^*c*^](#t3n3){ref-type="table-fn"}                                                                                1.03 (0.92, 1.14)                                            1.04 (0.89, 1.22)
   *p*-Value                                                                                                                                       0.60                                                         0.62
  PFDA                                                                                                                                                                                                            
   Tertile 1                                                      0.01--0.13 (0.09)          379            265                                 Reference                                                    Reference
   Tertile 2                                                      0.13--0.20 (0.16)          247            264                             0.62 (0.49, 0.79)                                            0.91 (0.64, 1.32)
   Tertile 3                                                      0.20--1.95 (0.27)          167            264                             0.43 (0.33, 0.56)                                            0.71 (0.48, 1.05)
   *p*-Trend[^*b*^](#t3n2){ref-type="table-fn"}                                                                                                 $< 0.0001$                                                      0.09
   $\text{Log}_{10}$ PFOS[^*c*^](#t3n3){ref-type="table-fn"}                                                                                0.72 (0.65, 0.81)                                            0.90 (0.77, 1.04)
   *p*-Value                                                                                                                                    $< 0.0001$                                                      0.16

Note: Model 1, conditioned on matching factors, including age, month of sample collection, fasting status, menopausal status and postmenopausal hormone use (premenopause, postmenopause and never use hormone, postmenopause and former or current use hormone, or missing). Model 2, further adjusted for family history of diabetes (yes, or no), oral contraceptive use (never used, past user, or current user), breastfeeding duration at blood draw (nulliparous or parous without breastfeeding, $\leq 11\,\text{months}$, or $\geq 12\,\text{months}$) and number of children delivered after 1993 (0, 1, or $\geq 2$), states of residence (coastal, Great Lakes region, or inland), smoking status (never, former, or current), alcohol intake (abstainer, $< 5.0\; g/d$, $5.0–14.9\; g/d$, or $\geq 15.0\; g/d$), physical activity (MET-h/wk, $< 3$, 3--8.9, 9--17.9, 18--26.9, or $\geq 27$), baseline BMI (kg/m^2^, $< 23.0$, 23.0--24.9, 25.0--29.9, 30.0--34.9, or $\geq 35.0$), and AHEI score (in quintiles). AHEI, alternative healthy eating index; BMI, body mass index; CI, confidence interval; MET, metabolic equivalent of task; OR, odds ratio; PFAS, perfluoroalkyl substances; PFDA, perfluorodecanoic acid; PFHxS, perfluorohexane sulfonic acid; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate.

Odds ratios according to batch-corrected PFAS tertiles were estimated using conditional logistic regression.

*p*-Values for trend were calculated by analyzing median PFAS values in each category as a continuous variable.

ORs for a 1-SD increase in $\text{Log}_{10}$-transformed PFASs, which were 0.2337381 for PFOS, 0.250798 for PFOA, 0.3580725 for PFHxS, 0.2636537 for PFNA, 0.2903877 for PFDA.

When modeling the associations for each SD increment of log-transformed PFASs, we found significantly higher T2D risk associated with PFOA \[$\text{OR} = 1.24$ (95% CI: 1.06, 1.45), $p = 0.009$\]. Dose--response curve ([Figure 1A](#f1){ref-type="fig"}) demonstrated a positive relationship between PFOS concentrations and T2D risk ($p = 0.02$) and a nonsignificant trend towards increased T2D risk at higher PFOA concentrations ([Figure 1B](#f1){ref-type="fig"}).

![Dose--response relationships of PFOS (*A*) and PFOA (*B*) concentrations with type 2 diabetes risk in the Nurses' Health Study II. The analysis was performed using restricted cubic spline regressions with 3 knots, and *p* for nonlinearity was examined by a likelihood ratio test comparing a model with a linear term only to the model with the linear plus cubic spline terms. Study participants with the lowest 2.5% and highest 2.5% of PFAS concentrations were excluded to minimize potential impact of outliers. Odds ratios (ORs) were estimated using cubic spline regression after adjusting for all covariates listed in the footnote of [Table 3](#t3){ref-type="table"}. PFOA, perfluorooctanoic acid; PFOS, perfluorooctanesulfonic acid. The solid lines represents ORs, and the dotted lines 95% confidence intervals.](EHP2619_f1){#f1}

When we restricted the analysis to batches with low CVs (within-batch CV% $< 20\%$), PFOS and PFOA remained associated with higher T2D risk after adjusting for matching variables and confounding factors (Model 2; see Table S4). Stratified analysis did not find significant interaction between time of diabetes diagnosis and baseline PFAS concentrations, nor did we observe interactions between PFASs and AHEI score (see Table S5).

Discussion {#s4}
==========

In U.S. nurses without known occupational exposure to PFASs, we observed significant associations between higher baseline concentrations of these chemicals, especially PFOS and PFOA, in plasma and an increased T2D risk during follow-up for an average of 6.7 y.

In our analysis, age was not a significant predictor of PFAS concentrations, probably reflecting the fact that blood samples were collected before the peak plasma concentrations, that is, before the production of PFOS and PFOA was phased out by U.S. producers ([@c41]). Unlike the lipophilic persistent organic pollutants, such as polychlorinated biphenyls that are significantly correlated with body adiposity ([@c9]; [@c81]), BMI was not a predictor of PFAS concentrations in our study, as was the case among participants in the National Health and Nutrition Examination Survey ([@c43]). In contrast, longer breastfeeding duration has been consistently associated with lower PFAS concentrations in women in the current and previous studies ([@c42]; [@c65]; [@c80]). Diet has been thought to be one of the primary exposure routes to PFASs among general populations without occupational exposure history; one study reported as much as 61% of total PFAS exposure could be due to diet ([@c67]). We also found that intakes of seafood, and popcorn were correlated with PFAS concentrations. Our findings are consistent with those from European countries ([@c13]; [@c17]; [@c67]). However, due to differences in food production and consumption, data from other populations may not be extrapolated to Americans. Dietary sources of PFASs in the United States are only partly known ([@c11]), and potential impacts of diet on observed associations between PFAS exposure and health outcomes remain to be elucidated.

The existing literature represents somewhat mixed evidence regarding the associations between PFAS exposure and diabetes risk. The largest cross-sectional investigation was from the C8 Health Project, in which estimated lifetime exposure showed no association with T2D risk or fasting glucose ([@c26]), whereas plasma concentrations of PFOA, PFOS, PFNA, and PFHxS were inversely associated with prevalent diabetes ([@c8]; [@c36]). Conversely, a study among Wisconsin male anglers found that several PFASs were positively associated with prevalent prediabetes and diabetes ([@c7]). Among Chinese living in Taiwan, a positive association of serum PFOS was seen with prevalent diabetes; however, PFOA, PFNA, and perfluoroundecanoic acid (PFUnA) showed inverse associations ([@c63]). In terms of prospective evidence, Cardenas et al. ([@c4]) found no significant association between PFASs and diabetes incidence ($n = 204$) among 957 participants from the Diabetes Prevention Program trial, which might be explained by the strong effects of lifestyle intervention that could have dwarfed the potential impacts of other risk factors on diabetes risk. The European Youth Heart Study found that plasma PFOA concentrations at 9 y of age were associated with decreased $\beta\text{-cell}$ function at adolescence (15 y of age), although not in early adulthood (21 y of age) ([@c10]). Development of gestational diabetes was associated with the serum PFOA concentrations in pregnant women, although another study showed less clear associations ([@c39]; [@c69]; [@c79]). These equivocal findings might be attributed to reverse causation by existing diabetes or prediabetes conditions linked to the cross-sectional study design used in most previous investigations. In addition, the dose--response relationship between PFAS exposures and diabetes incidence at different exposure concentrations is unknown. In the two studies reporting inverse associations of PFASs and T2D risk ([@c8]; [@c63]), serum PFAS concentrations were much higher than those observed in the current and other previous studies (mean $\text{PFOA}\,\text{concentrations} = 28\,\text{ng}/{mL}$ in the C8 Health Study, and mean PFOA, PFNA, and $\text{PFUnA} = 8.0$, 3.8, and $6.4\,\text{ng}/{mL}$, respectively, among Chinese adults). For the remaining studies ([@c4]; [@c7]; [@c10]; [@c39]; [@c69]; [@c79]), serum concentrations of PFOA and PFOSs were similar to or lower than those in our study. Further studies are needed to elucidate dose--related diabetogenic effects of PFAS exposure, and whether such effects of PFAS exposure may be age and/or sex dependent.

Potential mechanisms underlying associations between PFASs and T2D risk are unclear. Experimental studies have found that PFASs activate $\text{PPAR}\alpha$ ([@c53]; [@c75]) and $\text{PPAR}\gamma$ ([@c2]; [@c53]; [@c70]), which regulate energy homeostasis, lipid and glucose metabolism, and adipocyte differentiation and function ([@c1]). Accumulating evidence has also suggested that PFASs may also interfere with human metabolism through PPAR-independent pathways. For example, PFOA altered expression of proteins in human liver cells that are regulated by hepatocyte nuclear factor $4\alpha$ ([@c58]), which is a key regulator of lipid metabolism and gluconeogenesis ([@c19]; [@c52]) and is involved in thyroid hormone homeostasis ([@c44]). Recent evidence from *in vitro* studies has further demonstrated potentially estrogenic and antiestrogenic effects of PFASs ([@c21]; [@c30]). Furthermore, PFOA increases oxidative stress and mitochondrial dysfunction that lead to apoptosis and cytotoxicity in rat $\beta\text{-cell-derived}$ RIN-m5F cells ([@c64]). These mechanisms may contribute to the effects of subchronic, elevated exposures to PFASs on thyroid hormone homeostasis, liver toxicity, and body weight observed in animal experiments ([@c31]; [@c48]). More recent studies also reported that perinatal PFOS exposure in rats led to abnormalities of glucose and lipid homeostasis at adulthood ([@c35]; [@c72]). In addition, 4-wk treatment of adult mice with PFOA interfered with glucose metabolism and induced insulin hypersensitivity ([@c78]). Another *in vivo* study in mice showed that PFOA induced histopathological changes in the pancreas through increasing oxidative stress ([@c25]). In zebrafish, embryonic exposure to PFOS likewise led to abnormal pancreatic development ([@c57]). Although these studies explore different outcomes, in concert, they support that PFAS exposure may affect metabolic functions. However, given the apparent between-species differences in pharmacokinetics and tissue distribution of PFASs, as well as functional and structural differences in PPARs ([@c31]; [@c51]; [@c60], [@c59]), caution must be taken when extrapolating data regarding PFASs from animal studies to humans. We did not observe strong correlations between PFAS levels and established diabetes risk markers, such as adiponectin, insulin, or HbA1c, although the cross-sectional nature of these correlations excluded causal inference. Sporadic reports of human cross-sectional studies illustrated a possible link between PFASs exposures and altered thyroid or liver functions ([@c15]; [@c29]; [@c40]). Thus, impaired thyroid metabolism or liver functions may also play a role, whereas oxidative stress and estrogenic effects observed in experimental studies are among other possible modes of action that may explain the PFASs--T2D associations. In addition, it is possible that PFASs have stronger effects among individuals at a higher risk of diabetes (e.g., overweight) or during periods of weight change (e.g., growth spurts in childhood and puberty) ([@c10]; [@c66]), which warrant investigations in future studies.

The prospective study design, high follow-up rate, good quality of self-reported diet, lifestyle, and medical history in this medically literate study population; multivariate adjustment for T2D risk factors and predictors of PFAS exposures; and rigorous laboratory quality control procedures are among the major strengths of the current study. A few caveats deserve to be considered. First, the generalizability may be limited to U.S. female health professionals and similar groups without an occupational PFAS exposure history. Second, although the homogeneity in regard to the socioeconomic status may render the study population less subject to confounding, we cannot rule out the possibility that the observed associations could be partially due to residual or unmeasured confounding, especially by other pollutants that may be correlated with PFASs. Third, we assessed PFAS concentrations in one single blood sample and thus cannot exclude the possibility that PFAS long-term exposure concentrations might be somewhat misclassified, despite our pilot study demonstrating excellent reproducibility of the PFASs in blood samples collected 1--2 y apart. Such reproducibility is likely due to the long elimination half-lives of PFASs in the human circulation ([@c45]) and perhaps also a fairly stable, continuous exposure through diet, drinking water, and consumer products in the population studied. Fourth, we did not measure fasting glucose, thyroid hormones, estrogen metabolites, or other potential mediators that could possibly link PFAS exposure with T2D and therefore cannot determine whether the positive associations may be linked with these potential pathways.

In conclusion, higher baseline plasma concentrations of PFOS and PFOA were associated with an elevated incidence of T2D in a nested case--control study population of U.S. women followed from 1995 to 2011. These associations warrant attention in prospective cohort studies and in mechanistic studies to elucidate the dose--dependent links between PFASs exposure and T2D risk. Although the production of PFOS and PFOA has been voluntarily phased out in the United States, their persistence in the environment and in humans renders them a lasting concern in regard to human metabolic health.
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